---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-016496"
form_type: "8-K"
ticker: "PFSA"
cik: "0001859807"
company_name: "Profusa, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:49:51.790404+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Profusa signs exclusive worldwide license with Mayo Clinic for oxygen monitoring and CLTI

## Summary
- Profusa granted exclusive worldwide license from Mayo for patent rights in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI).
- Collaboration to support U.S. commercialization of Lumee wearable continuous tissue oxygen monitoring for critical limb ischemia.
- Potential new indications include cardiovascular, renal, multi-organ, and orthopedic postoperative perfusion monitoring.
- Profusa CEO notes over $100M invested in Lumee; Mayo retains financial interest for not-for-profit mission.
- Financial terms include royalties on net sales, milestone payments, and share of sublicense income.

## SEC filing metadata
- accession: 0001213900-26-016496
- form_type: 8-K
- ticker: PFSA
- cik: 0001859807
- company_name: Profusa, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859807/000121390026016496/0001213900-26-016496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859807/000121390026016496/ea0277026-8k_profusa.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-016496
- JSON: https://secwatch.observer/filing/0001213900-26-016496.json
- Plain text: https://secwatch.observer/filing/0001213900-26-016496.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.